EpiVax Oncology, Inc.

51 articles about EpiVax Oncology, Inc.

• Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach

  8/11/2023

  EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.

• Providence-based "Biotech start up" EpiVax Celebrates 25th Anniversary

  5/17/2023

  EpiVax, Inc. is celebrating its 25th birthday by renewing the company's commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company.

• EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™

  1/10/2023

  EpiVax, Inc. ("EpiVax") and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2.

• EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

  10/31/2022

  EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.

• EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products

  9/12/2022

  EpiVax, Inc. is pleased to announce the award of a two-year, $2 million grant from the FDA's Office of Center for Drug Evaluation and Research to validate a method for immunogenicity risk assessment of host cell proteins for improving biosimilar product development and assessing product interchangeability.

• EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers of Immunology

  11/17/2021

  EpiVax, Inc. announces the publication of three papers focusing on malaria vaccine efficacy, in collaboration with Leidos, the University of Georgia Center for Vaccines and Immunology, the University of Oxford's Jenner Institute, and Sanofi Pasteur's VaxDesign Campus.

• EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

  5/17/2021

  EpiVax, Inc. ("EpiVax") announces the publication "Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation" in NPJ Vaccines .

• EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)

  2/17/2021

  EpiVax, Inc. announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, and better accessibility.

• EpiVax Announces Licensing of Immunogenicity Screening Toolkit, ISPRI, to AbCellera

  6/8/2020

  EpiVax, Inc. ("EpiVax") a Rhode Island -based company and recognized leader in the field of immunogenicity assessment today announced it has licensed its advanced in silico toolkit for biologics immunogenicity screening, ISPRI, to AbCellera Biologics Inc. ("AbCellera").

• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: April 10

  4/10/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
• 

  Biopharma Update on the Novel Coronavirus: April 8

  4/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.

• EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries

  4/7/2020

  EpiVax, Inc., is using advanced computational tools to accelerate a COVID-19 vaccine candidate for healthcare workers into clinical trials in 6 months.

• EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

  3/26/2020

  EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

• Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

  3/4/2020

  Coronavirus nCOV-2019 antigenic epitopes predicted by EpiVax computational vaccinology and epitope prediction tools to be linked with Ii-Key to generate peptide vaccines against COVID-19

• EpiVax Oncology Appoints Daniel Adams as Chairman of the Board of Directors

  1/27/2020

  EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the appointment of Daniel Adams as Chairman of the Board of Directors.

• EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

  12/23/2019

  EpiVax continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020.

• EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports

  11/6/2019

  EpiVax, Inc., a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in Scientific Reports, 06 Nov 2019, a Nature publication.

• EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)

  10/23/2019

  EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that three abstracts highlighting its Ancer™ platform have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland.

• Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment

  10/22/2019

  ugai Pharmaceutical Co., Ltd., a member of the Roche Group, will extend the company's licensed access to the Immunogenicity Screening and Protein Reengineering Interface toolkit developed by EpiVax, Inc.